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Background: Loss of function mutations in 3-Hydroxyacyl-CoA Dehydrogenase (HADH) cause protein sensitive
hyperinsulinaemic hypoglycaemia (HH). HADH encodes short chain 3-hydroxacyl-CoA dehydrogenase, an enzyme
that catalyses the penultimate reaction in mitochondrial β-oxidation of fatty acids. Mutations in GLUD1 encoding
glutamate dehydrogenase, also cause protein sensitive HH (due to leucine sensitivity). Reports suggest a
protein-protein interaction between HADH and GDH. This study was undertaken in order to understand the
mechanism of protein sensitivity in patients with HADH mutations.
Methods: An oral leucine tolerance test was conducted in controls and nine patients with HADH mutations. Basal
GDH activity and the effect of GTP were determined in lymphoblast homogenates from 4 patients and 3 controls.
Immunoprecipitation was conducted in patient and control lymphoblasts to investigate protein interactions.
Results: Patients demonstrated severe HH (glucose range 1.7–3.2 mmol/l; insulin range 4.8-63.8 mU/l) in response
to the oral leucine load, this HH was not observed in control patients subjected to the same leucine load. Basal
GDH activity and half maximal inhibitory concentration of GTP was similar in patients and controls. HADH protein
could be co-immunoprecipitated with GDH protein in control samples but not in patient samples.
Conclusions: We conclude that GDH and HADH have a direct protein-protein interaction, which is lost in patients
with HADH mutations causing leucine induced HH. This is not associated with loss of inhibitory effect of GTP on
GDH (as in patients with GLUD1 mutations).
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HADH encodes 3-hydroxyacyl-CoA dehydrogenase
(HADH), an intra-mitochondrial enzyme that catalyses
the penultimate reaction in fatty acid β-oxidation. HADH
is highly expressed in pancreatic β-cells [1] and plays an
important, but as yet unknown, role in the regulation of
insulin secretion [2,3]. The pivotal role of HADH in pan-
creatic β-cells is supported by the existence of dysregu-
lated insulin secretion (hyperinsulinaemic hypoglycaemia;
HH) in patients with HADH mutations. We recently* Correspondence: khalid.hussain@ucl.ac.uk
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reproduction in any medium, provided the orireported that patients with HH due to recessively inher-
ited HADH mutations are protein sensitive [4]; this ob-
servation demonstrates that HADH somehow regulates
protein-induced insulin secretion.
Protein-sensitive HH, due to leucine sensitivity, is also
known to be associated with the hyperinsulinism-
hyperammonaemia syndrome (HI/HA syndrome) [5], a
condition characterised by HH and asymptomatic hyper-
ammonaemia. HI/HA syndrome is caused by missense
mutations in the GLUD1 gene that encodes the mito-
chondrial enzyme glutamate dehydrogenase (GDH),
which catalyses the oxidative deamination of glutamate
to α-ketoglutarate and ammonia. In the pancreatic β-cell,
α-ketoglutarate enters the tricarboxylic acid cycle and
leads to insulin secretion. GDH is allosterically activatedtral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
ginal work is properly cited.
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ing mutations in GLUD1 reduce the sensitivity of the
enzyme to allosteric inhibition by GTP and ATP leading
to increased leucine-induced glutamate deamination [5].
Hence patients with HI/HA syndrome develop
hypoglycaemia following ingestion of leucine.
A recent study [6] suggests the existence of an inter-
action between HADH and glutamate dehydrogenase
(GDH) in the pancreatic β-cell. Even more recently,
studies on hadh −/− mice have confirmed this in pan-
creas and other organs. [7] It could hence be hypothe-
sized that HADH deficiency causes protein-sensitive HH
due to leucine sensitivity via the GDH axis. In this model
of HADH and GDH interaction, HADH would act as an
inhibitor of GDH, regulating leucine stimulated insulin
secretion. Loss of function mutations in HADH would
hence be associated with loss of GDH inhibition or
raised GDH activity, a feature of GLUD1 mutations. In
order to test this hypothesis, we investigated whether
patients with protein sensitive HH due to HADH muta-
tions are leucine sensitive and whether they have
increased basal GDH activity and loss of GTP inhibition,
as seen in patients with HI/HA syndrome. We also
investigated whether the HADH/GDH protein inter-
action exists in patient and control lymphoblasts.
Methods
Nine patients previously reported by us to have HH due
to recessively inherited mutations in HADH were studied
[4,8-10]. The clinical characteristics of the patients are
summarised in Table 1.
Leucine tolerance test
Nine patients and seven controls (aged-matched children
being investigated for other causes of hypoglycaemia) under-
went an oral leucine load test. Diazoxide administration to
patients was stopped 24 hours before the test and patients
were managed with regular feeds or IV dextrose as neces-














Pt 1 16 weeks +0.25 P258L 10.5 4.4
Pt 2 16 weeks -1.1 IVS6-2a>g 10 4.4
Pt 3 16 weeks -0.11 M188V 4.2 5.1
Pt 4 5 days +1.69 R236X 2.1 4.8
Pt 5 1 week +1.23 R236X 6.6 5.5
Pt 6 16 weeks -0.71 K136E 3.2 6.6
Pt 7 16 weeks -1.85 Q163X 7.8 5.0
Pt 8 2 weeks +1.16 R236X 1.3 4.8
Pt 9 2 days +0.93 Ex1del/Ex1del 2 4.2L-Leucine was administered. Blood glucose and plasma in-
sulin concentrations were measured at 15 minute intervals.
The test was stopped at 120mins, or earlier if hypoglycaemia
(defined as blood glucose concentration of </=3.0 mmol/l)
developed.
GDH activity
Peripheral blood samples were obtained from four
patients with HADH mutations and lymphocytes from
these patients were transformed with Epstein–Barr virus
to establish lymphoblast cultures. Glutamate dehydrogen-
ase activity in lymphoblast homogenates was determined
spectrophotometrically, as NADH oxidation at 340 nm
with α-ketoglutarate as the substrate [11]. The IC50 for
GTP was determined by addition of GTP (50nM –
1000nM) to the assay. Protein content was determined by
the Bradford assay [12].
Co-immunoprecipitation
GDH was immunoprecipitated from 300 μg lymphoblast
mitochondrial lysate (3 controls and 4 patients with
mutations in HADH (Refs 10, 4, 8, 9.)) (prepared using a
Mitosciences mitochondria isolation kit for cultured cells
according to the manufacturer’s instructions) using a
rabbit polyclonal antibody and protein A sepharose.
Immunoprecipitated proteins were denatured in SDS-
sample buffer and separated by SDS-polyacrylamide elec-
trophoresis. 50 μg of whole lymphoblast lysate was also
run on one of the gels for control and patient samples.
The gel was transferred to a nitrocellulose membrane
and subjected to immunostaining with a monoclonal
antibody to HADH overnight and peroxidase conjugated
secondary antibody for 1 hour. Proteins were visualised
using an Amersham Healthcare ECL+ kit.
Results
Clinical characteristics
The median birth weight of the patients with a mutation















2.7 9.5 45 45 8
1.7 6.5 63.8 30 9
2.7 8.6 31.7 30 4
2.8 12.9 25.12 30 10
2.2 <2 13.6 45 10
3.0 <2 4.8 90 10
2.7 <2 5.6 90 10
3.0 2.2 9.2 60 10
2.8 <2 23.9 60 10
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marised in Table 1. All patients with HADH mutations
were diazoxide-responsive and demonstrated normal
fasting tolerance on diazoxide.
Leucine tolerance test
All nine subjects with HADH deficiency developed
hypoglycaemia after oral leucine load, at a median time
of 45 minutes (Figure 1a). None of the control subjects
became hypoglycaemic after the leucine load (Figure 1b)
Table 1 summarises the blood glucose and insulin
responses to the oral leucine load in patients.
GDH activity
Basal GDH activity was not significantly different in
lymphoblast homogenates from 4 patients and 3 controls
(Figure 2a), and IC50 for GTP is not higher in patients
with mutations in the HADH gene. In patients with
HI/HA syndrome caused by mutations in the GLUD1
gene, higher than usual basal enzyme activities can be
seen and the inhibitory effect of GTP on GDH is lost
[13,14].
Co-immunoprecipitation
When GDH is immunoprecipitated from control human
lymphoblasts using a polyclonal antibody, HADH is also
pulled down as picked up by monoclonal HADH anti-
body (Figure 2b.1, Lanes 4,5 and 6, Figure 2b.2., Lane 1).
This protein interaction between HADH and GDH in
normal lymphoblasts does not occur in the 4 patient
samples (Figure 2b.1, Lane 3, Figure 2b.2., Lanes 2,3,4).
Figure 2b.1 also demonstrates that HADH protein is well
expressed in control lymphoblasts (Lane 2).
Discussion
Leucine-induced HH is a feature of the HI/HA syn-
drome and is due to gain of function mutations in





























Figure 1 Blood glucose concentrations in response to the oral leucine
patients demonstrated marked hypoglycaemia (blood glucose concentratio
none of the control subjects developed hypoglycaemia in response to an othe tricarboxylic acid cycle and leads to an increase in
the concentration of cellular ATP. This rise in the cellu-
lar ATP causes closure of the ATP sensitive potassium
channel (KATP channel); resulting in cell membrane
depolarization, Ca2+ influx via voltage gated calcium
channels and insulin exocytosis.
GDH is allosterically activated by leucine and inhibited
by GTP [15]. Activating mutations in the GLUD1 gene
reduce the sensitivity of the enzyme to allosteric inhib-
ition by GTP and ATP [14] or less frequently cause an
increase in the basal GDH activity [13]. The loss of inhib-
ition by GTP leads to increased leucine induced glutam-
ate oxidation to α-ketoglutarate. Hence leucine sensitivity
is manifested by hypoglycaemia following protein-rich
meals which is a classical feature of this condition [5,16].
The mechanism of persistent hyperammonaemia is not
completely understood, although a recent paper by
Treberg et al [17] suggests that this is due to renal
ammoniagenesis.
Protein sensitivity (but no leucine sensitivity) is also a
feature observed in patients with mutations in the KATP
channel genes [18]. We recently described severe protein
sensitivity in patients with loss of function mutations in
the HADH gene [4]. We now show for the first time, in
a larger number of patients, that loss of function muta-
tions in the HADH gene causes severe leucine hypersen-
sitivity. These clinical observations suggest that HADH
acts in some way to limit leucine induced insulin secre-
tion. Interestingly, in contrast to patients with muta-
tions in the GLUD1 gene the serum ammonia level is
not elevated in patients with HADH mutations (data
not shown). Our results show that despite the leucine
hypersensitivity, mutations in HADH do not cause an
increase either in the basal activity of GDH, or a change
in the IC50 for GTP. This suggests that HADH muta-
tions cause leucine sensitivity and dysregulated insulin

























load in the nine patients with a mutation in HADH. All the
n of </= 3.0 mmol/l) in response to the leucine load (1a). In contrast,
ral protein load (1b).
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Figure 2 GDH enzyme activity in control and patient lymphoblasts (a) Activity was measured, either without GTP or with increasing
concentrations of GTP (0 – 1000nM) to determine the IC50. Activities are reported +/− SEM. (b.1.) Western blot of 50ug whole lymphoblast
lysates (Lane 1 patient, Lane 2 control) or 300ug mitochondrial lymphoblast lysates immunoprecipitated with 1ug GDH rabbit polyclonal antibody
(Lane 3 patient, Lanes 4–6 controls) then probed with mouse monoclonal antibody to HADH. (White lines indicated unused lanes cut out, all
samples on same gel) (b.2.) Western blot of 300 μg mitochondrial lymphoblast lysates immunoprecipitated with 1 μg GDH rabbit polyclonal
antibody (Lane 1 control, Lanes 2–4 patient samples) then probed with mouse monoclonal antibody to HADH.
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exists between GDH and HADH thus suggesting that
HADH in some way regulates the activity of GDH. This
regulatory mechanism would not seem to involve GTP
but must occur by another as yet unidentified mechan-
ism. It is possible that an interaction between HADH
and GDH has allosteric effects that affect how leucine
stimulates GDH activity. Reduced expression of HADH
protein, which can be seen in patient lymphoblasts,
could allow leucine to over stimulate GDH and hence
lead to excessive insulin secretion. In support of this hy-
pothesis Li et al [7] have shown an interaction between
HADH and GDH both in liver mitochondria and islets
from hadh +/+ but not hadh −/− mice. In hadh −/− liver
His-tagged HADH was used to immunoprecipitate GDH
as identified by mass spectrometry but this was not the
only protein pulled down, it may be speculated that this
could be true of islet cells also. Interestingly, basalactivity of GDH in islets were similar in +/+ and −/− is-
lets and also the GTP IC50 which agrees with our data
on human lymphoblasts. Li et al [7] also showed a
reduced Km for α-ketoglutarate in hadh −/− islets that
was not seen in −/− liver or kidney which resulted in a
50 % increase in enzyme efficiency. This increase in en-
zyme efficiency shown in pancreas may be due to the
fact that HADH is so highly expressed [1] in this organ
compared to others, that a deficiency of it is detrimental
with regard to regulation of GDH. In other organs the
expression of HADH is much lower and so does not
have the same effect on GDH. This highlights the dif-
ference between patients with mutations in GDH where
activity of this enzyme is affected in all tissues in the
body.
HH on administration of leucine was demonstrated in
the hadh −/− mouse by Li et al [7]. This HH was exacer-
bated by the addition of glutamine and alanine and it is
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be responsive to these amino acids.
Martens et al [3] showed that expression of HADH in
pancreatic β-cells is higher than that of other enzymes of
β–oxidation pathway suggesting an important role for
this protein in β–cell physiology. Li et al [7] show that
the ratio of HADH to GDH mRNA was 5 fold higher in
mouse islets than in liver. Martens et al [3] showed how-
ever that suppression of the HADH protein resulted in
increased basal and glucose stimulated insulin secretion
which was not due to increased rates of glucose metabol-
ism or an inhibition of fatty acid oxidation. The data
obtained by Li et al [7] suggested that deletion of HADH
protein caused an increase in basal islet metabolism but
that this did not have a major effect on glucose stimu-
lated insulin secretion. These data appear to contradict
each other but may be due to an incomplete KO of
HADH in the study by Martens et al [3].
Conclusions
In conclusion, our clinical data indicates that the protein
sensitivity seen in patients with HADH mutations is
caused by leucine. The biochemical data reveals that this
is not due to an increase in GDH activity, and shows for
the first time that in control human lymphoblasts a pro-
tein-protein interaction exists between HADH and
GADH that is not seen in lymphoblasts with HADH
mutations. This, in conjuction with the hadh −/− mouse
data [7] suggest that the protein interaction modifies
GDH action in some way that allows dysregulated insulin
secretion. Further research in this area is required to
fully understand the way in which the interaction dis-
rupts insulin secretion and how amino acid metabolism
and fatty acid oxidation are linked by these two enzymes.
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